Toggle navigation
Menu
Home
News
Local
National
World
Politics
Sports
Entertainment
Business
Health
News Tip Hotline
Weather
Bend
Traffic
Live Traffic Cams
Central Oregon
Mountain Passes
Road Reports
Trip Check
Gas Prices
Closures and Delays
Stations
KQAK-FM 105.7
The Peak 104.1
The Ranch 95.7 FM
KBNW-AM/FM
KRCO-AM
Events
Upcoming
Concerts
Submit An Event
Submit A PSA
Interviews
Inside Central Oregon
Central Oregon Spotlight
Water Wise Tips
HBG Interviews
Ray’s Random Questions
Just Used Cars as Heard on KQAK & The Ranch
About MCO
Contact/About Us
Advertise
Careers
Media Kit
Radio Stations
Contest Rules
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Edgewise Therapeutics, Inc. - Common Stock
(NQ:
EWTX
)
39.91
-1.27 (-3.07%)
Delayed Quote
Updated: 4:00 PM EST, Nov 20, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Edgewise Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
Next >
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc. - EWTX
August 17, 2025
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc. - EWTX
August 13, 2025
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc. - EWTX
August 09, 2025
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc. - EWTX
August 05, 2025
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc. - EWTX
August 01, 2025
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc. - EWTX
July 28, 2025
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc. - EWTX
July 23, 2025
From
Pomerantz LLP
Via
GlobeNewswire
EWTX Investors Have Opportunity to Join Edgewise Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
July 19, 2025
From
The Schall Law Firm
Via
Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc. - EWTX
July 18, 2025
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Edgewise Therapeutics, Inc. - EWTX
July 14, 2025
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc. - EWTX
July 10, 2025
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc. - EWTX
July 03, 2025
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc. - EWTX
July 01, 2025
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc. - EWTX
June 30, 2025
Via
ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc. - EWTX
June 28, 2025
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc. - EWTX
June 26, 2025
Via
ACCESS Newswire
Edgewise Therapeutics to Present on Sevasemten for the Treatment of Becker Muscular Dystrophy at the 2025 MDA Clinical and Scientific Conference
March 11, 2025
From
Edgewise Therapeutics
Via
Business Wire
Edgewise Therapeutics to Present at the Leerink Partners Global Healthcare Conference on March 11, 2025
March 04, 2025
From
Edgewise Therapeutics
Via
Business Wire
Edgewise Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
March 03, 2025
From
Edgewise Therapeutics, Inc.
Via
Business Wire
Edgewise Therapeutics Strengthens Leadership Team to Support Late-Stage Clinical Development
January 22, 2025
From
Edgewise Therapeutics
Via
Business Wire
Edgewise Therapeutics Provides Corporate Update and Highlights Priorities for 2025
January 13, 2025
From
Edgewise Therapeutics
Via
Business Wire
Edgewise Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025
January 07, 2025
From
Edgewise Therapeutics
Via
Business Wire
Edgewise Therapeutics Announces Positive Topline Results from the CANYON Phase 2 Trial of Sevasemten in Individuals with Becker Muscular Dystrophy (Becker)
December 16, 2024
From
Edgewise Therapeutics
Via
Business Wire
Edgewise Provides Statement Regarding Company’s Relationship with Dr. Han Phan at Rare Disease Research
December 05, 2024
From
Edgewise Therapeutics
Via
Business Wire
Edgewise Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference on December 3, 2024
November 26, 2024
From
Edgewise Therapeutics
Via
Business Wire
Edgewise Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
November 07, 2024
From
Edgewise Therapeutics
Via
Business Wire
Edgewise Therapeutics to Present on Sevasemten (EDG-5506) for Becker Muscular Dystrophy (Becker) at the 29th International Annual Congress of the World Muscle Society
October 01, 2024
From
Edgewise Therapeutics
Via
Business Wire
MarketBeat Week in Review – 9/23 - 9/27
September 28, 2024
Stocks had a mostly bullish week as stimulus efforts in the U.S. and China enhanced risk-on sentiment, but next week's jobs report could spark a larger rally
Via
MarketBeat
Topics
Economy
Analysts Think There's Still Time to Get in on Edgewise, Up 332%
September 25, 2024
Edgewise Therapeutics was a massive winner last week after positive results on its cardiovascular treatment. This there still room for the stock to run?
Via
MarketBeat
Edgewise Therapeutics Soars 50%: Key Reasons Behind the Surge
September 19, 2024
Edgewise Therapeutics is rocketing higher on positive results for its HCM combating treatment and short-covering. Expect volatility in the weeks ahead.
Via
MarketBeat
< Previous
1
2
3
4
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
581446795
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/60.0.3112.113 Safari/537.36
00fbf3724072e3a4c643b60a8db5a8756c4f8c05
1